Research and Training Funding

Funding Opportunity Announcements

Browse below for Data Science Funding Opportunity Announcements.

This page last reviewed on August 7, 2019

Feed last updated: January 25 2020 11:49 am
Title FOA Number Organization Release Date Expiration Date Purpose Search Terms
Notice of Special Interest: Availability of Administrative Supplements to NIH Science Education Partnership Awards (SEPA) to Fund Participation in the NOT-GM-20-006 NIGMS Nov 18 2019 N/A Notice Special Interest: Availability Administrative Supplements NIH Science Education Partnership Awards SEPA) Fund Participation the NIH Pavilion the 2020 USA Science & Engineering Festival USASEF) Notice Number: NOT-GM-20-006 Key Dates Release Date: November 18, 2019 First Available Due Date: December 19, 2019 Expiration Date: December 20, 2019 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional)" Issued National Institute General Medical Sciences NIGMS) Purpose National Institute General Medical Sciences NIGMS) announces availability administrative supplements Science Education Partnership Awards SEPA) projects. purpose this Notice to support development interactive exhibits health, biomedical behavioral science topics be featured the 2020 USA Science Engineering Festival USAEF) NIH Pavilion related activities the festival. goals these supplements to: educate public via interactive face-to-face exhibits the wonders science, technology, engineering mathematics STEM); inspire next generation scientists engineers; showcase cutting-edge technological impact SEPA STEM projects. Exhibit topics must address or of 6 target categories: Infectious Diseases & Microbes; Molecules & Cells; Lifestyle, Diet, Disparities; Brain; Bioengineering; Data Science. Application Submission Information Applications this initiative must submitted using following opportunity. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions: Application Due Date: December 19, 2019 funding consideration, applicants should include NOT-GM-20-006” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Requests be more 25,000 direct costs exclusive Facilities Administrative F&A) costs. more 40% the request go the collaborator(s) subcontractors. Requests be 4 months support only. Only administrative supplement request per SEPA be accepted process Streamlined Submissions using eRA Commons cannot used this initiative. Research Strategy limited 6 pages. the Research Strategy, applications should: 1) clearly describe significance the proposed exhibit; 2) align the operational design concepts inherent interactive science fair exhibits, e.g., high excitement value is sufficient excite communicate science content moderate throughput time ( 3 – 5 min) keep wait time short; 3) include the project team SEPA PD(s)/PI(s) 2 – 4 SEPA students will participate facilitators near-peer role models. NIGMS also encourages participation, justification, key project staff. Supplement requests related other NIH activities the USASEF, such the stage shows, also accepted. Research Strategy section the application should include: Description the exhibit, participant interactions anticipated educational outcomes Images the proposed exhibit Approximate dimensions/footprint, limited 10 x10 feet pavilion activities Electrical requirements Computer/IT requirements requirements description how students the SEPA project be included the development execution the proposed exhibit. proposed exhibit must within scope the parent SEPA project. Eligible investigators strongly encouraged contact Scientific/Research contacts listed below prior submitting application.     Inquiries Please direct inquiries to: Tony Beck, PhD National Institute General Medical Sciences NIGMS) Email: beckl@mail.nin.gov Behrous Davani, PhD National Institute General Medical Sciences NIGMS) Email: behrous.davani@nih.gov
Notice of Special Interest: Administrative Supplement for Research on Bioethical Issues (Admin Supp Clinical Trial Optional) NOT-OD-20-038 NIH Dec 30 2019 N/A Notice Special Interest: Administrative Supplement Research Bioethical Issues Admin Supp Clinical Trial Optional) Notice Number: NOT-OD-20-038 Key Dates Release Date: December 30, 2019 First Available Due Date: January 24, 2020 Expiration Date: March 20, 2020 Related Announcements PA-19-217 PA-18-591 Issued Office The Director, National Institutes Health OD) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) Fogarty International Center FIC) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) Sexual Gender Minority Research Office SGMRO) National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Office Research Women's Health ORWH) Tribal Health Research Office THRO) Purpose NIH Office Science Policy OSP) within Office the Director OD) announces availability administrative supplements support research bioethical issues develop evidence base may inform future policy directions. Applicants propose supplement parent awards focused bioethics to add component related bioethics a parent award which bioethics not focus. Note applications must within general scope the parent award. applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers: Office Behavioral Social Sciences Research OBSSR), Office Research Women’s Health ORWH), Sexual Gender Minority Research Office SGMRO), the Tribal Health Research Office THRO). Background Ethical considerations intrinsic the responsible conduct biomedical research the translation scientific technological advances practice. Research bioethical issues provide evidentiary basis guide conduct, content, and/or application the biomedical behavioral sciences their associated policies, becomes increasing importance science societal views continue evolve. Ethical questions challenges interlinked many NIH’s general areas scientific priority, such responding public health needs e.g., opioid crisis, desire precision medicine interventions) emerging scientific opportunities e.g., new data sharing infrastructure, innovative technologies). investment and integration bioethics-related research policy demonstrates NIH’s commitment safeguarding integrity the research it conducts supports, which, turn, facilitates public participation trust the research enterprise. administrative supplement funding opportunity announcement provide opportunity NIH-supported researchers support research bioethical issues develop evidence base may inform future policy directions. Applicants propose supplement parent awards focused bioethics to add component related bioethics a parent award which bioethics not focus. Specific Areas Research Interest NIH seeks fund research ethical considerations related biomedical research. Applications projects do propose research question research aim specific a bioethical issue may inform future policy directions e.g. applications propose only support training educational activities do involve investigation a research question) not considered. Issues interest fall within scope research supported the NIH may beyond focus any Institute Center. Applications should propose research topics can provide evidence base may inform future policy directions, includes current future NIH-issued policies, federal policies, laws, regulations, well policies governing practice research medicine. Overarching areas research interest include are limited to: New emerging technology development use, such as: gene editing; organoids; artificial intelligence; machine learning; brain implants modulation; digital health; consumer-generated data; synthetic biology Clinical non-clinical data sharing; big data data science analytics; integration data research, including clinical, research, environment, social media, participant/patient provided, other data types; biases datasets algorithms Precision personalized medicine Personal, institutional, research privacy security Learning Healthcare System; interface clinical research clinical care; pragmatic trials; real-world data Crowdsourcing, citizen science, DIY biomedical research Participant driven, directed, sponsored clinical research Patient/participant representation research oversight study design, including appropriate return research results incidental findings Special vulnerable population research, including pediatric, palliative care, emergency, disaster, pandemic research Individual community health, treatment, and/or research disparities; accessing sharing benefits research; post-study obligations Issues related the inclusion Tribal American Indian/Alaska Native populations Issues related the inclusion populations underrepresented research, including issues related inclusion and research sexual gender minorities Current emerging regulatory policy environments, including NIH policy Innovative study design, conduct, management, oversight, including methods obtaining documenting informed consent; virtual clinical trials International research including research resource-constrained settings, transnational research, research low middle income countries Research stigmatized conditions Historical analyses bioethics issues Novel approaches developing, enhancing, measuring effectiveness of, bioethics infrastructure training New means enhancing assessing scientific workforce, including policies promote scientific workforce diversity inclusion promote safe inclusive research environment addition overarching areas interest, individual NIH Institutes, Centers, Offices indicated following specific areas research interest: FIC Fogarty International Center FIC) interested research ethical issues relevant low- middle-income countries, particular, studies conducted investigators these countries. of Us Research Program All Us Research Program interested applications address topics relevant its core mission. Please note at time, recontact All Us Research Program participants not possible. program in process developing requisite policies technical infrastructure support ancillary studies, including ELSI research, will notify researchers these capabilities become available. NCI National Cancer Institute NCI) interested bioethics issues relevant cancer research care, such issues raised cancer clinical trials, cohort studies, cancer prevention studies, cancer centers, prospective biobanking, projects using existing samples/tissues. Bioethical issues interest include are limited issues raised new therapies/technologies; issues raised the of ancestry markers vs. ethnicity/race research treatment; innovative methods recruitment retention participants are underserved, hard reach,” otherwise underrepresented research; participant, community, patient engagement; return research results; participant patient perception comprehension; effective communication including patient-provider to/within families); increasing access care populations cancer disparities. Additional issues be found here: https://epi.grants.cancer.gov/bioethics-cancer-research.html. NCI encourages investigators contact parent grant program officer address any budgetary issues prior submitting supplement application NHGRI National Human Genome Research Institute NHGRI) interested applications investigate address bioethical issues related the of genetics genomics research, clinical medicine healthcare, society. NHGRI supports studies specific conditions diseases only the proposed work produce knowledge is generalizable transferable other genetic conditions. Research the implications new emerging genomic technologies novel uses existing technologies particularly encouraged. Examples include, are limited to: use polygenic risk scores diverse ancestral populations, synthetic biology the application artificial intelligence and/or machine learning genomic data. NHLBI National Heart, Lung, Blood Institute NHLBI) interested research bioethics issues relevant its Strategic Vision https://www.nhlbi.nih.gov/about/strategic-vision), its focus heart, lung, blood, sleep conditions. Specific examples include, are limited The return research results e.g., genomic, omic, environmental) context participants communities, such environmental toxins may impact community health, handoff between research clinical care, providing genetic counseling large scales Issues related clinical trials, including adaptive clinical trial designs, usual care” arms, other novel designs Bioethical questions related implementation science research Waivers informed consent, exceptions informed consent, obtaining consent surrogates Ethics cardiopulmonary support Novel emerging technologies, such machine learning bias algorithm overreach physician autonomy Privacy confidentiality especially large datasets), such artificial intelligence applied imaging data concerns may arise multi-omics profiles impact NIH policy changes, such updates the management genomic summary results Issues related working understudied vulnerable populations creating culturally-appropriate messaging Investigators encouraged contact NHLBI staff discuss ideas NCATS National Center Advancing Translational Sciences NCATS) interested research ethical issues cross disease domains span translational research spectrum. NCATS encourages collaboration between translational researchers bioethics researchers projects addressing ethical challenges moving discoveries laboratory, clinic, community interventions improve health. Note concerning Award Project Period: Supplement project budget periods limited the remaining active budget period started FY20 the existing parent award. be eligible, parent award must active i.e. be an extension period), the activities proposed the supplement must accomplished within remaining active budget period started FY20 the existing parent award. earliest anticipated start date July 1, 2020. NIMHD National Institute Minority Health Health Disparities NIMHD) interested supporting research projects the ethical, legal, social implications research participation and/or health care racial/ethnic minority other health disparity populations. Areas interest NIMHD include are limited studies seek understand address cultural preferences; values norms ensure ethical equitable conduct research delivery health care; ethical integration social biomedical sciences e.g., social epigenomics incorporation social determinants the health care system); mitigating stigmatization, group harms, unintended social implications research. NIAAA National Institute Alcohol Abuse Alcoholism NIAAA) interested bioethics applications address topics relevant its mission research priorities provided its strategic plan. information, please see: https://www.niaaa.nih.gov/strategic-plan NIAID NIAID interested supporting supplemental projects focus ethical issues relevant domestic international collaborative research HIV/AIDS its co-morbidities TB, malaria, hepatitis, sexually transmitted infections), infectious diseases, immunologic allergic diseases; ethics clinical trials implementation science; ethical issues relevant NIAID's scientific mission. Applications include conceptual work bioethics, empirical work gathering analyzing data relevant ethical issues research, a combination the two. empirical projects, data collection include quantitative qualitative methods, both. Although intended be exhaustive list, particular interest projects Ethical issues research involving adolescents young adults Ethical issues research preventing, treating, curing HIV Ethical, legal policy issues the intersections public health surveillance, care delivery, research Ethics research involving child-bearing age pregnant women Applications addressing empirical research informed consent not interest NIAMS mission The National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) to support research the causes, treatment, prevention arthritis musculoskeletal skin diseases; training basic clinical scientists carry this research; the dissemination information research progress these diseases. NIAMS also conducts supports basic research the normal structure function bones, joints, muscles, skin. Clinical research areas include rheumatology, orthopedics, dermatology, metabolic bone diseases, heritable disorders bone cartilage, inherited inflammatory muscle diseases, sports rehabilitation medicine. NIAMS interested bioethics topics relevant its core mission. NIBIB National Institute Biomedical Imaging Bioengineering NIBIB) interested bioethics research relevant its mission support development innovative technologies bioimaging bioengineering. Areas particular interest NIBIB include, are limited to, ethical issues related to: artificial intelligence machine learning; digital health wearable/implantable technologies; clinical decision support systems healthcare professionals, caregivers, and/or patients); data sharing, privacy, security; synthetic biological systems; neuromodulation technologies; health disparities inclusion biomedical research. Investigators strongly encouraged contact NIBIB staff discuss ideas. more information areas interest the NIBIB, please visit: https://www.nibib.nih.gov/research-funding NIDDK National Institute Diabetes Digestive Kidney Diseases NIDDK) interested applications address topics relevant its core mission. more information, please see: NIDDK Research Areas NCCIH National Center Complementary Integrative Health NCCIH) interested bioethics applications address topics relevant its mission research priorities provided its strategic plan. information, please see: https://nccih.nih.gov/about/plans NICHD Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) interested bioethical issues relevant research involving children, pregnant women, people disabilities. Research the fields developmental biology, reproductive health, pediatrics, population health, medical rehabilitation, research addresses health disparities improves prevention efforts among populations served NICHD, well areas identified high-priority research areas the institute of particular interest. https://www.nichd.nih.gov/grants-contracts/research-areas/priorities the current research priorities the institute in https://www.nichd.nih.gov/about/org/strategicplan regarding future themes the Institute. NIDCD National Institute Deafness Other Communications Disorders NIDCD) interested applications address topics the areas hearing, balance, taste, smell, voice, speech, language. more information, please see: NIDCD Strategic Plan NIDCR National Institute Dental Craniofacial Research NIDCR) interested applications propose bioethics research relevant dental, oral, craniofacial health. more information, please see: https://www.nidcr.nih.gov/about-us/mission. addition the overarching priority areas this notice related dental, oral, craniofacial health, NIDCR also interested in: Return incidental findings overall health clinical non-clinical data e.g., genome-wide omics data) produced studies focus dental, oral craniofacial phenotypes Privacy, confidentiality, data re-use other ethical issues clinical non-clinical data, particularly large scale facial image data omics data NIDA National Institute Drug Abuse NIDA) interested bioethics applications address topics relevant its mission research priorities provided its strategic plan, including research involving pregnant women using substances. more information, please see: https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan NINDS National Institute Neurological Disorders Stroke NINDS) interested research bioethical neuroethical questions relevant its mission seek fundamental knowledge the brain nervous system to that knowledge reduce burden neurological disease. addition the general areas interest listed above, areas interest specific NINDS include are limited the ethical implications of: aspects neuroscience research human participants, such differing stakeholder views trial design, return research results participants, patient consent-related issues, therapeutic misconception including rare diseases); research brain organoids ex vivo human brain tissue; collecting sharing human brain data, such de-identification, privacy, re-use practices; development use neuromodulation neuroimaging technologies, such device maintenance, data security, intended unintended uses these technologies; predictive/diagnostic research related brain disorders; advances neural recording and/or neuromodulation specifically use children. Additional information the NINDS mission be found here: http://www.ninds.nih.gov/about_ninds/mission.htm. Note applications must consider bioethical and/or neuroethical questions be within general scope the parent award. Also, NINDS not consider supplement applications include basic research activities research vertebrate animals. NINR NINR interested studies examining bioethical issues related end life palliative care EOLPC) research consider including not limited to): EOLPC needs individuals serious, advanced illness, particularly vulnerable populations such as: children, frail elderly, individuals limited decision-making capacity. Prioritization patient preferences, beliefs, values respect treatment and/or end life decision making. needs/challenges families, caregivers, proxy decision makers individuals serious, advanced illness. Disparities access EOLPC individuals across settings urban, rural, remote), including differences among socioeconomic, racial/ethnic geographic sub-populations. Because the complex, multi-factorial nature this issue, multi-disciplinary teams highly encouraged NIEHS National Institute Environmental Health Sciences NIEHS) is interested bioethics applications address topics relevant its mission research priorities provided its strategic plan. information, please see: https://www.niehs.nih.gov/about/strategicplan/index.cfm NIA National Institute Aging NIA) interested applications address topics relevant its core mission. more information, please see: https://www.nia.nih.gov/about/mission NIMH National Institute Mental Health NIMH) interested bioethics applications address topics relevant its mission research priorities provided its strategic plan. information, please see: https://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml Office Research Women’s Health Office Research Women’s Health ORWH) focuses research is relevant the health women is interested research bioethics issues intersect the goals, objectives, guiding principles the trans-NIH Strategic Plan Women’s Health Research https://orwh.od.nih.gov/about/trans-nih-strategic-plan-womens-health-res...). Specific examples include, are limited to: Ethical, legal, social implications sex and/or gender differences research across lifespan; the ethics the consideration sex/gender intersectionality basic, translational, clinical research inclusion and/or exclusion understudied, underrepresented, underreported populations women research i.e. pregnant lactating women, incarcerated women, young girls, women color, women health disparities, sex gender minority women, women disabilities, women living rural areas); their retention research Ethical issues governing retainment advancement women biomedical careers i.e. power dynamics and/or differentials, gender harassment, hiring, promotion tenure); issues related women participating team science conducting interdisciplinary and/or trans-disciplinary research. Bioethical issues derived data generated research development R&D) drugs, medical devices, emerging technologies, along health screenings i.e. mammograms, Pap-smears, newborn screening, EKG) Societal implications, such stigma based gender, related sex and/or gender bias considerations the development use novel emerging technologies i.e. artificial intelligence, machine learning, multi-accuracy auditing, digital/mobile health, social media tools) Sex/gender neuroethics ethics related sex gender considerations genomic research precision medicine Ethical issues around provider-patient interactions/relationships family caregiving related its impact women’s health well-being Scope Support number awards contingent upon NIH appropriations the submission a sufficient number meritorious applications. Office the Director intends commit least 2,000,000 FY 2020 fund approximately 10 awards Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions: Application Due Date(s) – March 20, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-OD-20-038 ” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Application budget cannot exceed maximum direct cost 100,000. addition the direct cost, applicable F&A indirect) costs also requested. Requests be one year support only. Research Strategy section the application limited 6 pages. criteria review Section V. Application Review Criteria PA-18-591 be followed, except the following criteria be used instead the criteria provided Overall Impact: NIH staff consider ability the proposed supplement activities increase preserve parent award’s overall impact within original scope award appropriate: the administrative supplement increase preserve likelihood the project exert influence the bioethics-related policy the research field(s) involved? the administrative supplement provide evidence base may inform future policy directions? Does administrative supplement address bioethical issue is pressing, recurring, and/or emerging biomedical research? the overall strategy, methodology, analyses proposed the supplement application well-reasoned appropriate accomplish proposed research a one-year period? process Streamlined Submissions using eRA Commons cannot used this initiative. Applicant organizations submit than application, provided each sufficiently distinct any administrative supplement currently under consideration the awarding NIH Institute Center. Only application per parent award be submitted. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Inquiries Please direct inquiries to: Scientific/Research Contact(s) Wendy Weber, N.D., Ph.D., M.P.H. National Center Complementary Integrative Health NCCIH) Telephone: 301-402-1272 Email: weberwj@mail.nih.gov Kristina McLinden, PhD National Institute Aging Telephone: 301-827-2563 Email: mclindenka@nih.gov Shari Feirman, Ph.D. Office Science Policy/Office the Director OSP/OD) Telephone: 301-435-6350 Email: shari.feirman@nih.gov Nicole Lockhart, Ph.D. National Human Genome Research Institute NHGRI) Telephone: 301-480-2493 Email: lockhani@mail.nih.go Tammara Jenkins, MSN, RN, PCNS-BC Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-435-6837 Email: tjenkins@mail.nih.gov Khara Ramos, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-594-2614 Email: khara.ramos@nih.gov Mollie Minear, Ph.D. National Heart, Lung, Blood Institute NHLBI) Telephone: 301-435-0448 Email: mollie.minear@nih.gov Barbara Sina, Ph.D. Fogarty International Center FIC) Telephone: 301-402-9467 Email: sinab@mail.nih.gov Elaine Collier, M.D. National Center Advancing Translational Sciences NCATS) Telephone: 301-435-0794 Email: colliere@mail.nih.gov Charlisse Caga-anan, J.D. National Cancer Institute NCI) Telephone: 240-276-6738 Email: charlisse.caga-anan@nih.gov Pamela Wernett, Ph.D. National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-827-5391 Email: wernettpj@mail.nih.gov Joana Roe National Institute Allergies Infectious Disease NIAID) Telephone: 240-627-3213 Email: Joana.Roe@nih.gov Marisol Espinoza-Pintucci, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-827-6959 Email: marisol.espinoza-pintucci@nih.gov Todd Merchak National Institute Biomedical Imaging Bioengineering NIBIB) Telephone: 301-496-8592 Email: merchakt@mail.nih.gov Trinh Ly, M.D. National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-435-4085 Email: trinh.ly@nih.gov Leslie Frieden, Ph.D. National Institute Dental Craniofacial Research NIDCR) Telephone: 301-496-4263 Email: leslie.frieden@nih.go Aynur Unalp-Arida, MD, MSc, PhD National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-8879 Email: aynur.unalp-arida@nih.go Ruben Baler, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-480-2733 Email: baler@nida.nih.gov Nancy Jones, Ph.D., M.A. National Institute Minority Health Disparities NIMHD) Telephone: 301-594-8945 Email: jonesna@nimhd.nih.gov Lynn Adams, Ph.D. National Institute Nursing Research NINR) Telephone: 301-594-8911 Email: adamsls@mail.nih.gov Jamie White, M.S. Office Research Women’s Health/Office the Director ORWH/OD) Telephone: 301-496-9200 Email: Jamie.white@nih.gov Subhashini Chandrasekharan, Ph.D. of Us Research Program/Office the Director AoURP/OD) Email: subhashini.chandrasekharan@nih.go Lindsey Martin, PhD National Institute Environmental Health Sciences Telephone: 984.287.4036 Email: lindsey.martin@nih.gov James Churchill, Ph.D. National Institute Mental Health NIMH) Telephone: 301-443-3621 Email: churchillj@mail.nih.gov Wendy Weber, ND, PhD, MPH National Center Complementary Integrative Health NCCIH) Telephone: 301-402-1272 Email: weberwj@mail.nih.gov Peer Review Contact(s) Applicable Financial/Grants Management Contact(s) Shelley Carow National Center Complementary Integrative Health NCCIH) Telephone: 301-594-3788 Email: carows@mail.nih.gov Jeff Ball National Institute Aging Telephone: 301-403-7736 Email: ballj@nia.nih.gov Bryan Clark, MBA Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-435-6975 Email: clarkb1@mail.nih.gov Tijuana Decoster, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone 301-496-9531 Email: decostert@mail.nih.gov Monique Day, Ph.D. National Institute Biomedical Imaging Bioengineering NIBIB) Telephone: 301-451-4797 Email: Monique.day@nih.gov Bruce Butrum Fogarty International Center FIC) Telephone: 301-496-2075 Email: butrumb@mail.nih.gov Tawana McKeither National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-9238 Email: tawana.mckeither@nih.gov Harvey Kincaid National Center Advancing Translational Sciences NCATS) Telephone: 301-435-0850 Email: harvey.kincaid@nih.gov Crystal Wolfrey National Cancer Institute NCI) Telephone: 240-276-6277 Email: wolfreyc@gab.nci.nih.gov Deanna Ingersoll National Human Genome Research Institute NHGRI) Telephone: 301-435-7858 Email: Deanna.Ingersoll@nih.gov Judy Fox National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-4704 Email: jfox@mail.nih.gov Dhana Khurana National Institute Allergies Infectious Disease NIAID) Telephone: 240-669-2966 Email: Vandhana.Khurana@nih.gov Leslie Littlejohn National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5055 Email: Leslie.Littlejohn@nih.gov Christopher Myers National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-435-0713 Email: myersc@mail.nih.gov Diana Rutberg, M.B.A. National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4798 Email: rutbergd@mail.nih.gov Pamela G. Fleming National Institute Drug Abuse NIDA) Telephone: 301-480-1159 Email: pfleming@nida.nih.gov Priscilla Grant, JD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-8412 Email: pg38h@nih.gov Ronald Wertz National Institute Nursing Research NINR) Telephone: 301) 594-2807 Email: wertzr@mail.nih.gov Elizabeth Spencer Office Research Women’s Health/Office the Director ORWH/OD) Telephone: 301-435-1057 Email: Elizabeth.spencer@nih.gov Kim Stanton National Health Lung Blood Institute NHLBI) of Us Research Program/Office the Director AoURP/OD)) Telephone: 301-827-8054 Email: stantonk@mail.nih.gov Thuthuy Nguyen National Institute Diabetes Digestive Kidney Diseases NIDDK) 301-594-8825 thuthuynguyen@niddk.nih.gov Theresa Jarosik National Institute Mental Health NIMH) Telephone: 301-443-3858 Email: Theresa.Jarosik@nih.gov Shelley Carow National Center Complementary Integrative Health NCCIH) Telephone: 301-594-3788 Email: CarowS@mail.nih.gov
Notice of Special Interest for Small Business Research in Genomics NOT-GM-19-041 NIGMS May 15 2019 N/A Notice Special Interest Small Business Research Genomics Notice Number: NOT-GM-19-041 Key Dates Release Date: 15, 2019 Related Announcements PAR-18-779 - Novel Genomic Technology Development R43/R44 Clinical Trial Allowed) PAR-19-061 -Computational Genomics Data Science Opportunities Small Business R43/R44 Clinical Trial Allowed) PA-19-043 - Novel Approaches Relating Genetic Variation Function Disease R43/R44 Clinical Trial Allowed) PA-19-034 - Commercializing Understudied Proteins the Illuminating Druggable Genome Project IDG) R43/R44 Clinical Trial Allowed) Issued National Institute General Medical Sciences NIGMS) Purpose National Institute General Medical Sciences NIGMS) issuing Notice highlight interest receiving Small Business Innovation Research SBIR) Small Business Technology Transfer STTR) grant applications focused the following areas: Improvement methodology technology) genetic analysis e.g., gene expression, probes), including procedures the separation analysis nucleic acids proteins these relate genetic problems. Improvement procedures statistical, computational, laboratory) the analysis gene flow gene dynamics human populations. Development improved vectors gene transfer. Development tools technologies detect monitor complex human phenotypes traits. Improvement procedures statistical, computational, laboratory) the high- medium-throughput analysis gene expression patterns regulatory networks. Development improvement methods high throughput detection epigenomic changes. Development improved novel methodology structure/function analysis very large macromolecular complexes involved transmission expression genetic material. Development new innovative tools methods bioinformatics computational biology. Development tools technologies a biomedical data science ecosystem biomedical research. Technologies findability, interconnectivity, interoperability biomedical data sets resources, integration existing data management tools development new ones, universalization innovative algorithms tools. Development ontologies modules useful combining mining databases containing genotype phenotype information order discover correlations drug effects, either therapeutic adverse. Development methods strategies characterize function kinases, ion channels G-protein coupled receptors development cell signaling molecules signaling intermediates, particularly those related G-protein coupled receptors ultimately leading the commercialization understudied proteins identified the Illuminating Druggable Genome" project. Application Submission Information Notice applies application due dates the dates indicated below subsequent due dates through expiration date the FOA. following funding opportunity announcements FOAs) must used submissions this initiative. Although NIGMS not listed a Participating Organization the FOAs listed below, applications this initiative be accepted. Activity Code FOA First Available Due Date R43/R44 PAR-18-779, Novel Genomic Technology Development R43/R44 Clinical Trial Allowed) September 5, 2019 R43/R44 PAR-19-061, Computational Genomics Data Science Opportunities Small Business R43/R44 Clinical Trial Allowed) September 5, 2019 R43/R44 PA-19-043, Novel Approaches Relating Genetic Variation Function Disease R43/R44 Clinical Trial Allowed) September 5, 2019 R43/R44 PA-19-034, Commercializing Understudied Proteins the Illuminating Druggable Genome Project IDG) R43/R44 Clinical Trial Allowed) September 5, 2019 instructions the SF424 R&R) Application Guide and listed funding opportunity announcements must followed, the following additions: funding consideration, applicants must include NOT-GM-19-041" (without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications non-responsive terms this Notice be withdrawn. Inquiries Please direct inquiries to: Scientific/Research Contact: Dmitriy Krepkiy, Ph.D. National Institute General Medical Sciences Email: dmitriy.krepkiy@nih.gov Financial Grants Management Contact: Brian Iglesias National Institute General Medical Sciences Email: iglesiab@mail.nih.gov data science, computational, bioinformatics, computational biology
Notice of Special Interest (NOSI): Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship Awards to Support Training in Research Relate NOT-OD-20-020 NIH Dec 06 2019 N/A Notice Special Interest NOSI): Ruth L. Kirschstein National Research Service Award NRSA) Fellowship Awards Support Training Research Related Down Syndrome Part the INCLUDE Project Notice Number: NOT-OD-20-020 Key Dates Release Date: December 6, 2019 First Available Due Date: April 08, 2020 Expiration Date: January 08, 2022 Related Announcements NOT-OD-20-024 NOT-OD-20-023 NOT-OD-20-012 Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project PA-19-191 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-192 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 - Diversity) PA-19-188 Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) RFA-OD-20-004 RFA-OD-20-003 RFA-OD-20-005 RFA-OD-20-006 RFA-OD-20-007NOT-OD-20-025 NOT-OD-20-022 Issued Office The Director, National Institutes Health OD) National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases (NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome DS) common co-occurring conditions also seen the general population while increasing pipeline DS investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan?, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives Notice Special Interest NOSI) announces NIH support the professional development trainees aiming establish career DS-related research. providing scientists training, resources, mentorship, NIH intends foster pipeline investigators DS other intellectual disabilities will lead future research improve understanding the biology DS support development new treatments health conditions experienced those DS. Investigators early their careers e.g., predoctoral candidates) well those advanced degrees e.g., PhD, MD) benefit mentorship established investigators professionals the DS research community basic science fields well clinical translational arenas. NIH issuing NOSI expand community investigators conducting research related DS encouraging scientists physicians early their research careers develop research projects related co-occurring conditions associated DS. Sharing resources effective communication outputs the broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). list of Funding Priorities Institute Center for project available the INCLUDE website. Applications response this NOSI should aligned the overall INCLUDE Project Research Plan, consists three components: Component 1: Targeted, high risk-high reward, basic science studies areas highly relevant Down syndrome Component 2: Cohort Study connect existing resources expand inclusion individuals Down syndrome Component 3: Inclusive clinical trials research co-occurring conditions individuals Down syndrome Projects propose recruit subjects DS encouraged promote enrollment research subjects the DS patient registry supported NIH, DS-Connect®. other data biospecimens human genetic non-genetic studies, awardees encouraged use biorepositories designated INCLUDE staff meet requirements broad sharing. NIH resource describing Common Data Elements may helpful during planning phases a project considering ways optimize data collection order facilitate broad data sharing. Application Submission Information Notice applies due dates or after April 8, 2020 expires January 8, 2022. Applications response this NOSI must submitted using of following target funding opportunity Announcements FOAs) their reissued equivalents. Although all NIH components indicated above listed Participating Organizations all FOAs listed below, applications this special topic be accepted. PA-19-191 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-192 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 - Diversity) PA-19-188 Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) instructions the SF424 R&R) Application Guide and listed funding opportunity announcements must followed, the following addition: funding consideration, applicants must include NOT-OD-20-020 in Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: list of contacts for participating NIH Institute Center available the INCLUDE website.    
Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across NOT-OD-20-025 NIH Dec 18 2019 N/A Notice Special Interest NOSI): NIH Research Project Grants Down Syndrome R01) the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project Notice Number: NOT-OD-20-025 Key Dates Release Date: December 18, 2019 First Available Due Date: February 05, 2020 Expiration Date: January 08, 2022 Related AnnouncementsNOT-OD-20-022 NOT-OD-20-012 Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project PA-19-055 Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-091 NIH Research Project Grant Parent R01 Basic Experimental Studies Humans Required NOT-OD-20-017 Notice Special Interest NOSI) Encourage Development Animal Models Related Biological Materials Research Related Down Syndrome NOT-OD-20-020 Notice Special Interest NOSI): Ruth L. Kirschstein National Research Service Award NRSA) Fellowship Awards Support Training Research Related Down Syndrome Part the INCLUDE Project NOT-OD-20-021 Notice Special Interest NOSI): Mentored Career Development Awards Support Training Research Related Down Syndrome Part the INCLUDE Project NOT-OD-20-022 Notice Special Interest: Administrative Supplements the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndrome) Project NIH-funded K12 KL2 Institutional Career Development Awards NOT-OD-20-023 Notice Special Interest: Availability Competitive Supplements/Revisions the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndromE) Project Competitive Supplement/Revision Clinical Trial Optional) NOT-OD-20-024 Notice Special Interest: Availability Administrative Supplements the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project NOT-OD-20-025 Notice Special Interest: NIH Research Project Grants Down Syndrome R01) RFA-OD-20-003 Clinical Trials Development Co-Occurring Conditions Individuals Down syndrome: Phased Awards INCLUDE R61/R33 Clinical Trial Required) RFA-OD-20-004 INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Clinical Trial Readiness R21 Clinical Trial Allowed) RFA-OD-20-005 Transformative Research Award the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndrome) Project R01 Clinical Trial Allowed) RFA-OD-20-006 Small Research Grants Analyses Down Syndrome-related Research Data the INCLUDE Project R03 Clinical Trial Allowed) RFA-OD-20-007 Development the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndromE) Project Data Coordinating Center U2C) Issued Office The Director, National Institutes Health OD) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Minority Health Health Disparities NIMHD) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome DS) common co-occurring conditions also seen the general population while increasing pipeline DS investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives purpose this Notice Special Interest NOSI) to support research project grant R01) applications are focused Down syndrome that meet programmatic objectives the INCLUDE Project. Sharing resources effective communication outputs appropriate interest broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). list of Funding Priorities Institute Center is available the INCLUDE website. Applications response this NOSI should aligned the overall INCLUDE Project Research Plan, consists three components: Component 1: Targeted, high risk-high reward, basic science studies areas highly relevant Down syndrome Component 2: Cohort Study connect existing resources expand inclusion individuals Down syndrome Component 3: Inclusive clinical trials research co-occurring conditions individuals Down syndrome Projects propose recruit subjects Down syndrome encouraged promote enrollment research subjects the Down syndrome patient registry supported NIH, DS-Connect®. other data biospecimens human genetic non-genetic studies, awardees encouraged use biorepositories designated INCLUDE staff meet requirements broad sharing. NIH resource describing Common Data Elements may helpful during planning phases a project considering ways optimize data collection order facilitate broad data sharing. INCLUDE website a list of Funding Priorities Institute Center for project, well list of contacts for participating NIH Institute Center. Program Directors/Principal Investigators PD/PIs) planning submit applications response this NOSI strongly encouraged contact scientific contacts this NOSI prior submission be advised appropriateness the intended resource research plans this program, competitiveness a potential application, alignment program priorities the INCLUDE initiative. Application Submission Information Notice applies due dates or after February 5, 2020 subsequent receipt dates through September 7, 2022. following Funding Opportunity Announcements FOAs) their reissued equivalents must used submissions this initiative. Although all NIH components indicated above listed Participating Organizations all FOAs listed below, applications this initiative be accepted the participating Institutes Centers NIH. PA-19-055 - NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 - NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-091 - NIH Research Project Grant Parent R01 Basic Experimental Studies Humans Required) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include NOT-OD-20-025 the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Applications nonresponsive terms this NOSI be withdrawn consideration this initiative.   Inquiries Please direct inquiries to: Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: list of contacts for participating NIH Institute Center available the INCLUDE website.  
Notice of Special Interest (NOSI): Modeling Social Contagion of Substance Use Epidemics NOT-DA-20-009 NIDA Jan 02 2020 N/A Notice Special Interest NOSI): Modeling Social Contagion Substance Epidemics Notice Number: NOT-DA-20-009 Key Dates Release Date: January 02, 2020 First Available Due Date: February 05, 2020 Expiration Date: January 08, 2023 Related Announcements PA-19-056: NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-055: NIH Research Project Grant Parent R01 Clinical Trial Required PA-19-091 NIH Research Project Grant Parent R01 Basic Experimental Studies Humans Required) PA-19-052: NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-092: NIH Exploratory/Developmental Research Grant Program Parent R21 Basic Experimental Studies Humans Required) PA-19-053: NIH Exploratory/Developmental Research Grant Program Parent R21 Clinical Trial Allowed) PA-19-054: NIH Exploratory/Developmental Research Grant Program Parent R21 Clinical Trial Required) Issued National Institute Drug Abuse NIDA) Purpose purpose this Notice to inform potential applicants the National Institute Drug Abuse NIDA) special interest research projects involving application social network theory study social contagion behaviors associated substance disorders can provide insight the prediction prevention the contagion substance epidemics. Applications should use large data sets data science approaches develop computational models social networks examine association between social influence substance use/misuse among individuals their peers. Background Social contagion the spread affect behavior person person among larger groups. Social network theory study how people, organizations, groups interact others inside network) its analysis been recent focus public health issues. Although has primarily used analyze predict transmission infectious diseases, social network theory also applied chronic behavioral conditions, including substance disorders, social factors their interactions age sex important determinants substance use. Research Objectives NIDA interested projects leverage big data sets utilize machine learning algorithms gain new knowledge related the behaviors associated substance disorders that facilitate prediction, prevention response epidemics substance disorders. Analyses should involve large datasets data science approaches develop computational models social networks examine substance use/misuse peer use/misuse propagated among social networks. Areas programmatic interest NIDA include, are limited to: Whether next epidemic substance disorders/secular trends substance behaviors be predicted social network analysis e.g., crack epidemic the 1990s the current opioid epidemic) social networks be used prevent epidemics related or caused substance behaviors social networks impact substance use, misuse, recovery processes New adapted interventions leverage social networks prevent substance use, misuse support recovery processes Relationships between “in real life” virtual social networks influencing substance behaviors recovery Examination multigenerational social network models incorporate families family structures vectors social influence, including effects familial substance behaviors effects peer substance use/misuse individuals within social network influences interpersonal networks mass media substance use, misuse, recovery network structures e.g., strength ties) influence substance use, misuse, recovery role social media plays influencing substance use, misuse, recovery changes social network composition structure influence recovery processes Examination how social network structure composition among service providers e.g., behavioral health providers, police, physicians) influence substance behavior recovery outcomes people receiving services Application Submission Information: notice applies due dates or after date subsequent receipt dates through January 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcements through expiration date this notice. PA-19-056: NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-055: NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-091: NIH Research Project Grant Parent R01 Basic Experimental Studies Humans Required) PA-19-052: NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-092: NIH Exploratory/Developmental Research Grant Program Parent R21 Basic Experimental Studies Humans Required) PA-19-053: NIH Exploratory/Developmental Research Grant Program Parent R21 Clinical Trial Allowed) PA-19-054: NIH Exploratory/Developmental Research Grant Program Parent R21 Clinical Trial Required) instructions the SF424 R&R) Application Guide the funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include "NOT-DA-20-009" without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered responding a NOSI. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Susan Wright, PhD National Institute Drug Abuse NIDA) Telephone: 301) 402-6683 Email: susan.wright@nih.gov Peter Hartsock, PhD National Institute Drug Abuse NIDA) Telephone: 301) 402-1964 Email: peter.hartsock@nih.gov Peer Review Contact(s) Examine eRA Commons account review assignment contact information information appears weeks after submission due date). Financial/Grants Management Contact(s) Pamela G. Fleming National Institute Drug Abuse Telephone: 301) 480-1159 Email: pfleming@nida.nih.gov
Notice of Special Interest (NOSI): Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrom NOT-OD-20-021 NIH Dec 06 2019 N/A Notice Special Interest NOSI): Mentored Career Development Awards Foster Careers Investigators Pursuing Research Related Down syndrome Part the INCLUDE Project Notice Number: NOT-OD-20-021 Key Dates Release Date: December 6, 2019First Available Due Date:February 12, 2020 Expiration Date:January 08, 2022 Related Announcements NOT-OD-20-024 NOT-OD-20-023 NOT-OD-20-025 PA-19-126 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-084 Mentored Research Scientist Development Award Parent K01 Independent Basic Experimental Studies Humans Required) PA-19-116 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-086 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Basic Experimental Studies Humans Required) PA-19-118 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119 Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-087 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Basic Experimental Studies Humans Required) PA-19-129 NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130 NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-090 NIH Pathway Independence Award Parent K99/R00 Independent Basic Experimental Studies Humans Required) NOT-OD-20-012 Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project RFA-OD-20-004 - INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Clinical Trial Readiness R21 Clinical Trial Allowed) RFA-OD-20-003 Clinical Trials Development Co-Occurring Conditions Individuals Down syndrome: Phased Awards INCLUDE R61/R33 Clinical Trial Required) RFA-OD-20-005 - Transformative Research Award the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndrome) Project R01 Clinical Trial Allowed) RFA-OD-20-006 - Small Research Grants Analyses Down Syndrome-related Research Data the INCLUDE Project R03 Clinical Trial Allowed) RFA-OD-20-007 - Development the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndromE) Project Data Coordinating Center U2C Clinical Trial Allowed) NOT-OD-20-022 Issued Office The Director, National Institutes Health OD) National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome DS) common co-occurring conditions also seen the general population while increasing pipeline DS investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives Notice Special Interest NOSI) announces NIH support the professional development early career scientists aiming establish career DS-related research. providing scientists training, resources, mentorship, NIH intends foster pipeline investigators DS other intellectual disabilities will lead future research improve understanding the biology DS support development new treatments health conditions experienced those DS. NIH issuing NOSI expand community investigators conducting research related DS encouraging scientists physicians early their research careers develop research projects related co-occurring conditions associated DS. Sharing resources effective communication outputs the broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). list of Funding Priorities Institute Center for project available the INCLUDE website. Applications response this NOSI should aligned the overall INCLUDE Project Research Plan, consists three components: Component 1: Targeted, high risk-high reward, basic science studies areas highly relevant Down syndrome Component 2: Cohort Study connect existing resources expand inclusion individuals Down syndrome Component 3: Inclusive clinical trials research co-occurring conditions individuals Down syndrome Projects propose recruit subjects DS encouraged promote enrollment research subjects the DS patient registry supported NIH, DS-Connect®. other data biospecimens human genetic non-genetic studies, awardees encouraged use biorepositories designated INCLUDE staff meet requirements broad sharing. NIH resource describing Common Data Elements may helpful during planning phases a project considering ways optimize data collection order facilitate broad data sharing.? Application Submission Information Notice applies due dates or after February 12, 2020 expires January 8, 2022. Applications response this NOSI must submitted using of following target Funding Opportunity Announcements FOAs) their reissued equivalents. Although all NIH components indicated above listed Participating Organizations all FOAs listed below, applications this special topic be accepted. Activity Code FOA First Available Due Date K01 PA-19-126 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) Feb 12, 2020 K01 PA-19-127 Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) Feb 12, 2020 K01 PA-19-084 Mentored Research Scientist Development Award Parent K01 Independent Basic Experimental Studies Humans Required) Feb 12, 2020 K08 PA-19-116 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) Feb 12, 2020 K08 PA-19-117 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) Feb 12, 2020 K08 PA-19-086 Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Basic Experimental Studies Humans Required) Feb 12, 2020 K23 PA-19-118 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) Feb 12, 2020 K23 PA-19-119 Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) Feb 12, 2020 K23 PA-19-087 Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Basic Experimental Studies Humans Required) Feb 12, 2020 K99/R00 PA-19-129 NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) Feb 12, 2020 K99/R00 PA-19-130 NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) Feb 12, 2020 K99/R00 PA-19-090 NIH Pathway Independence Award Parent K99/R00 Independent Basic Experimental Studies Humans Required Feb 12, 2020 instructions the SF424 R&R) Application Guide and listed funding opportunity announcements must followed, the following additions: funding consideration, applicants must include NOT-OD-20-021 in Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be withdrawn consideration this initiative.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: list of contacts for participating NIH Institute Center available the INCLUDE website.    
Notice of Special Interest (NOSI): IDEA2Health: Innovative Data Evaluation and Analysis to Health (Parent R01 Clinical Trial Not Allowed) NOT-HL-19-712 NHLBI Aug 15 2019 N/A Notice Special Interest NOSI): IDEA2Health: Innovative Data Evaluation Analysis Health Parent R01 Clinical Trial Allowed) Notice Number: NOT-HL-19-712 Key Dates Release Date: August 15, 2019 First Available Due Date: October 5, 2019 Expiration Date: January 8, 2022 Related Announcements NOT-HL-19-678: Bold New Bioengineering Research Heart, Lung, Blood, Sleep Disorders Diseases NOT-HL-19-676: Integrative Omics Analysis NHLBI TOPMed Data PA-19-056: NIH Research Project Grant Parent R01 Clinical Trial Allowed) Issued National Heart, Lung, Blood Institute NHLBI) Purpose purpose this Notice Special Interest NOSI) to inform applicants the National Heart, Lung, Blood Institute NHLBI) an area special interest the development utilization data science methodologies gaining new insights improve health heart, lung, blood sleep HLBS) domains  . Background Vast quantities structured unstructured data, sources such high-dimensional medical imaging, satellite imagery spatial data, physiological signals, smart electronic mobile devices, currently being generated biomedical research use. However, numerous challenges exist the phases the analytics life cycle – data wrangling, model building, assessment deployment. specific examples issues challenges are: extracting value raw complex data; handling multicollinearity, missing values, confounding bias; auto-detecting outliers noise; improving misclassification precise analysis; optimizing predictability an independent data set. rise machine learning ML) artificial intelligence AI) techniques enabled advent relevant solutions impacting health help train” computer systems auto-tuning finding insights faster more accurately. address new challenges, NIH articulated specific priorities encourages rapid open sharing scientific efforts development dissemination innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). NHLBI also recognized need developing innovative data science approaches enhance integration, analysis, interpretation data multiple sources gain insights the biological, social, environmental, behavioral determinants associated HLBS health disease Objective 7, Leverage emerging opportunities data science open new frontiers, NHLBI Strategic Vision, NIH Publication 16-HL-6150). order stimulate novel approaches this field, NHLBI seeking applications will further novel broader of data science methods, to include team-based approaches these research efforts. is hoped research outputs i.e., data, metadata, tools, algorithms, program code, tutorials, findings, etc.) potentially lead impactful analytic decision-making both the individual public health levels. Potential new knowledge be gained include: improved understanding how environmental factors interact individuals impact onset clinical health/disease; automation identifying, classifying, subtyping a disease condition; optimization algorithms personalized treatment, precision medicine precision prevention HLBS diseases conditions; generation novel research hypotheses. Research Objectives specific research objectives this NOSI to: 1) stimulate advancement employment novel data science methods gaining novel insights; 2) enable innovative engineering solutions better faster data analytics; 3) communicate research outputs through open-science platforms. innovative methodologies data science focus on, example, artificial intelligence, machine learning, deep-learning, combinations these techniques. scope scientific questions must of relevance the mission NHLBI aligned within the NHLBI’s Strategic Vision, NIH Publication 16-HL-6150. Multiple principle investigators key personnel complementary disciplines example, biostatistics/statistics, mathematics; computer science, engineering; biology, medicine, environmental science, social science, etc.) encouraged jointly participate. Research plans actively adhere open-science FAIR Findable, Accessible, Interoperable, Reusable) principles be greatest interest NHLBI. Research outputs include need be limited open-source, reusable, high-quality metadata; smart tools; algorithms; documentation; supplemental materials; presentations conferences publications containing guidelines examples, tutorials, source code. Sharing resources effective communication outputs appropriate interest broader communities essential elements applications. topics related TOPMed computational systems biology analysis trans-omics data, please check NOT-HL-19-676. Application Submission Information notice applies due dates or after October 5, 2019, subsequent receipt dates through January 8, 2022. Applications response this Notice must submitted through NIH Parent Announcement PA-19-056: NIH Research Project Grant Parent R01 Clinical Trial Allowed). All instructions the SF424 R&R) Application Guide and PA-19-056 must followed, the following additions: IMPORTANT: funding consideration, applicants must include NOT-HL-19-712 in Agency Routing Identifier field Box 4b) the SF424 R&R) Form. Applications without information Box 4b not considered this initiative. Applications nonresponsive the terms this Notice be be considered this initiative. Investigators planning submit application response this NOSI strongly encouraged contact discuss proposed research/aims an NHLBI program officer listed this NOSI well advance the grant receipt date. Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Lucy L. Hsu National Heart, Lung, Blood Institute NHLBI) Telephone: 301-402-3276 Email: lucy.hsu@nih.gov     data science, computational, artificial intelligence, machine learning, deep learning, statistics
Notice of Special Interest (NOSI): Development of Animal Models of Down Syndrome and Related Biological Materials as Part of the INCLUDE (INvestigatio NOT-OD-20-017 NIH Dec 18 2019 N/A Notice Special Interest NOSI): Development Animal Models Down Syndrome Related Biological Materials Part the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project Notice Number: NOT-OD-20-017 Key Dates Release Date: December 18, 2019 First Available Due Date: January 27, 2020 Expiration Date: September 09, 2022 Related Announcements NOT-OD-20-024 NOT-OD-20-023 RFA-OD-19-027, Resource-Related Research Projects Development Animal Models Related Materials R24 Clinical Trials Not-Allowed)NOT-OD-20-025 PAR-19-369, Development Animal Models Related Biological Materials Research R21 Clinical Trial Allowed) NOT-OD-20-012, Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) ProjectNOT-OD-20-022 Issued National Institutes Health NIH) Division Program Coordination, Planning Strategic Initiatives, Office Research Infrastructure Programs ORIP) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome common co-occurring conditions also seen the general population while increasing pipeline Down syndrome investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives purpose this Notice Special Interest NOSI) to foster development and improve access animal models Down syndrome related materials information will advance preclinical basic science studies related Down syndrome. Sharing resources effective communication outputs broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). Examples animal models related materials may developed include, are limited to: Animal models studying fundamental biological mechanisms underlying Down syndrome; Genetic resources, antibodies other reagents quantifying characterizing macromolecules cells animal models Down syndrome, systems biology approaches, informatics tools resources, including artificial intelligence, machine learning deep phenotyping tools, generating novel hypotheses improving value animal models Down syndrome research; Complementary approaches the of animals, such animal-tissue-on-chip models, can simulate physiological pathophysiological processes capture complex dynamics interacting molecules, cells, tissues organs outside the whole organism Down syndrome research. Comparison existing Down syndrome animal models best understand health conditions individuals Down Syndrome. While multiple useful animal models available the community, careful comparison their distinct phenotypes critical. example, the mouse strains presently use, penetrance particular phenotypes benefit qualitative quantitative validation. important comparisons include effect background strain colony maintenance the genotype phenotype over time. Development rat, non-rodent vertebrate, nonhuman primate models Down syndrome are better suited answer specific questions concerning complex neurological, behavioral, other phenotypes occur humans Down Syndrome currently available mouse models. INCLUDE project particularly interested development animal models relevance the multiple organ systems affected individuals Down syndrome co-occurring conditions, such neurodevelopment, immune system dysregulation, Alzheimer’s disease, cancer, cardiovascular disease, autism. Applications supporting R21 exploratory research projects R24 resource-related research projects should directly submitted response this NOSI. Applications R21 awards should describe projects distinct those supported through traditional R01 mechanism. Long-term projects, projects designed increase knowledge a well-established area, not appropriate R21 awards. R21 grant activity intended encourage exploratory research projects foster constant infusion new ideas, techniques, points view Down syndrome-related research. Such projects assess new experimental system propose innovative of existing methodology, system model enhance Down syndrome-related research. studies involve considerable risk may lead a breakthrough Down syndrome research through development novel techniques, reagents, methodologies models. Applications R24 awards should propose development animal models related resources would serve broad areas Down syndrome-related research. R24 grant activity intended encourage resource-related research projects support basic preclinical research providing substantial amount readily available animal-related resources. Animal-related resources include mutant transgenic animals; related biological materials, such nucleic acids, proteins, cell lines, tissues; knowledge an animal’s genome, life cycle, molecular, cellular physiological phenotypes, behaviors. Program Directors/Principal Investigators PD/PIs) planning submit applications response this NOSI strongly encouraged contact scientific contacts this NOSI prior submission be advised appropriateness the intended resource research plans this program, competitiveness a potential application, alignment program priorities the INCLUDE initiative. Application Submission Information Notice applies due dates or after January 27, 2020 expires September 9, 2022. following funding opportunity announcements FOAs) their reissued equivalents must used submissions this initiative. Activity Code FOA Number Title First Available Due Date R24 RFA-OD-19-027, Resource-Related Research Projects Development Animal Models Related Materials R24 Clinical Trials Not-Allowed) January 27, 2020 R21 PAR-19-369, Development Animal Models Related Biological Materials Research R21 Clinical Trial Allowed) February 16, 2020 instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include NOT-OD-20-017 in Agency Routing Identifier field Box 4.b) the SF 424 R&R) Form. Applications without information Box 4.b not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative.   Inquiries Please direct inquiries to: Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Charlene Schramm, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301) 401-3793 Email: schrammc@nih.gov Sige Zou, PhD Office Research Infrastructure Programs ORIP) Telephone: 301) 435-0749 Email: zous@mail.nih.gov  
Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data NOT-LM-19-003 NLM Mar 19 2019 N/A Notice Special Interest NOSI): Computational Statistical Methods Enhance Discovery Health Data Notice Number: NOT-LM-19-003 Key Dates Release Date: March 19, 2019 Related Announcements PAR-18-896 Issued National Library Medicine NLM) Purpose National Library Medicine issuing Notice highlight interest receiving grant applications through NLM Research Grants Biomedical Informatics Data Science R01 Clinical Trial Optional) PAR 18-896), focused research reduce mitigate gaps errors health data sets. Background Recent successes the of data-centric artificial intelligence AI) methods such deep learning stimulating interest the promise harnessing large complex digital health data sets advance goals precision medicine. Applying AI methods large health data sets promises provide new powers discovery, diagnosis, prediction, decision support aimed improving health outcomes reducing healthcare costs. Numerous public datasets human non-human data available, a rich array specialized tools platforms be used studies applications. However, recent work identifying addressing systematic biases blind spots data, in AI systems derived that data, highlighted array potential problems fairness, accuracy, safety, reproducibility inferences conclusions. Work bias incompleteness health data sets includes studies find poor representation minority groups, seniors, women. See, example, https://www.eurekalert.org/pub_releases/2016-10/uoms-nsr100716.php, or https://datasociety.net/output/fairness-in-precision-medicine/?utm_sourc...). recent Wall Street Journal article https://www.wsj.com/articles/a-crucial-step-for-avoiding-ai-disasters-11...) noted computational tools developed a diverse team help avoid bias algorithms. Beyond problems biases other gaps data, research using health data humans requires special care protect sources the data see https://www.ncbi.nlm.nih.gov/pubmed?term=Barocas%2C%20Solon%5BAuthor%5D ). All Us Research Program https://allofus.nih.gov/) aims develop unbiased, representative health data resource, there many health data sets already use being constructed. Tools developed using biased incomplete data sets contribute erroneous analyses. Statistical fallacies representational errors unrelated the research question hand introduce systematic errors. core questions understanding mitigating and problems health data research are: can done, computationally and/or statistically, reduce mitigate gaps errors data sets used health research?" and, can improve tools used discovery, understanding, visualization health data sets their analyses?" Whether problem due incomplete health data inadequate tools, approaches needed strengthen reproducibility applicability data-centered research the etiology, epidemiology treatment health conditions. Research Objectives NLM invites research grant applications propose state the art methods approaches address problems large health data sets tools used analyze them, whether data drawn electronic health records public health data sets, biomedical imaging, omics repositories other biomedical social/behavioral data sets. Areas interest include are limited 1) developing testing computational statistical approaches applied large and/or merged health data sets holding human non-human data, a focus understanding characterizing gaps, errors, biases, other limitations the data inferences based the data; 2) exploring approaches correcting biases compensating missing data, including introduction debiasing techniques policies the of synthetic data; 3) testing new statistical algorithms other computational approaches strengthen research designs use specific types biomedical social/behavioral data; 4) generating metadata adequately characterizes data, including provenance, intended use, processes which was collected verified; 5) improving approaches integrating, mining, analyzing health data preserve confidentiality, accuracy, completeness overall security the data. Applicants should address ethical issues might arise their proposed approach. Application Submission Information Applications response this Notice must submitted through NLM’s funding opportunity announcement, PAR-18-896: NLM Research Grants Biomedical Informatics Data Science R01 Clinical Trial Optional). instructions PAR-18-896 must followed. Submissions should indicate they in response NOT-LM-19-003 Field 4.b the SF 424 R&R form. Program Directors/Principal Investigators PDs/PIs) planning submit applications this topic strongly encouraged contact scientific contact listed this Notice advice the appropriateness a potential application alignment NLM’s program priorities. Inquiries Please direct inquiries to: Alan Vanbiervliet, PhDNational Library Medicine/Extramural ProgramsTelephone: 301-594-4882Email: alan.vanbiervliet@nih.gov data science, computational, informatics, artificial intelligence, deep learning

Pages

XLS